Provided by Tiger Fintech (Singapore) Pte. Ltd.

Theriva Biologics

1.36
+0.03502.65%
Post-market: 1.360.00000.00%17:47 EDT
Volume:12.42K
Turnover:16.25K
Market Cap:3.77M
PE:-0.07
High:1.36
Open:1.26
Low:1.25
Close:1.32
Loading ...
Mar 31, 2025

Major Issues Report

Form 8-K - Current report
Mar 21, 2025

[Amend]Public Prospectus

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Mar 07, 2025

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 07, 2025

Major Issues Report

Form 8-K - Current report
Jan 21, 2025

[Amend]Public Prospectus

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Dec 10, 2024

Public Prospectus

Form S-1 - General form for registration of securities under the Securities Act of 1933
Dec 05, 2024

Major Issues Report

Form 8-K - Current report
Nov 20, 2024

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Nov 12, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 12, 2024

Major Issues Report

Form 8-K - Current report
Nov 01, 2024

Major Issues Report

Form 8-K - Current report
Oct 16, 2024

Major Issues Report

Form 8-K - Current report
Oct 03, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Oct 03, 2024

Major Issues Report

Form 8-K - Current report
Oct 02, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Sep 30, 2024

Major Issues Report

Form 8-K - Current report
Sep 23, 2024

Correspondence

Form CORRESP - Correspondence
Sep 23, 2024

[Amend]Public Prospectus

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Sep 23, 2024

Major Issues Report

Form 8-K - Current report
Sep 20, 2024

Correspondence

Form CORRESP - Correspondence